Blueprint Medicines Co. (NASDAQ:BPMC) Receives $103.94 Consensus PT from Analysts

Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation, nine have issued a buy recommendation and one has […]

Related Keywords

United States ,Canada ,Christopherk Murray ,Michael Landsittel ,Piper Sandler ,Leerink Partnrs ,Us Bancorp ,Needham Company ,Principal Financial Group Inc ,Blueprint Medicines Co ,Securities Exchange Commission ,Canada Life Assurance ,Nasdaq ,Mirae Asset Global Investments Co ,Blueprint Medicines Corporation ,Associates Corp ,Blueprint Medicines ,Get Free Report ,Medicines Trading Down ,Exchange Commission ,Asset Global Investments ,Financial Group ,Get Free ,Medicines Corporation ,Blueprint Medicines Daily ,